DIRECTOR COMPENSATION POLICY
Exhibit 10.16
DIRECTOR COMPENSATION POLICY
Effective upon the closing of the initial public offering of Arcadia Biosciences, Inc., a Delaware corporation (the “Company”), directors of the Company that are not employees of the Company (“Non-Employee Directors”) shall receive the following compensation for their service as a member of the Board of Directors (the “Board”) of the Company:
Cash Compensation
Annual Retainer for Board Service
Each Non-Employee Director shall be entitled to an annual cash retainer of Forty Thousand Dollars (US$40,000) (the “Annual Retainer”), payable quarterly in arrears, subject to such director’s continued service to the Company as a Non-Employee Director on the last day of the preceding quarter. Such amounts shall be prorated in the case of service for less than the entire quarter.
Annual Retainer for Chairman of the Board
In addition to the Annual Retainer, the Non-Employee Director serving as the Chairman of the Board shall receive an additional annual cash retainer of Twenty Thousand Dollars (US$20,000) (the “Chairman Annual Retainer”), payable quarterly in arrears, subject to such director’s continued service to the Company as the Chairman of the Board on the last day of the preceding quarter. Such amounts shall be prorated in the case of service for less than the entire quarter.
Annual Retainer for Board Committee Chairpersons
In addition to the Annual Retainer, a Non-Employee Director who serves as Chair of the Company’s Audit Committee, Compensation Committee or Nominating and Governance Committee shall be entitled to an additional annual cash retainer equal to Fifteen Thousand Dollars (US$15,000) (in the case of the Chair of the Audit Committee), Ten Thousand Dollars (US$10,000) (in the case of the Chair of the Compensation Committee), and/or Seven Thousand Five Hundred Dollars (US$7,500) (in the case of the Chair of the Nominating and Governance Committee), irrespective of the number of committees on which such director serves as Chair or as a member (collectively the “Chair Retainers”). Chair Retainers shall be payable quarterly in arrears, subject to such director’s continued service to the Company as a Chair of a committee on the last day of the preceding quarter. Such amounts shall be prorated in the case of service for less than the entire quarter.
Annual Retainer for Service on a Board Committee
In addition to the Annual Retainer, other than the Chair, each Non-Employee Director who serves as member of the Company’s Audit Committee, Compensation Committee or Nominating and Governance Committee shall be entitled to an additional annual cash retainer equal to Seven Thousand Five Hundred Dollars (US$7,500) (in the case of a member of the Audit Committee), Five Thousand Dollars (US$5,000) (in the case of a member of the Compensation Committee), and/or Three Thousand Seven Hundred Fifty Dollars (US$3,750) (in the case of a member of the Nominating and Governance Committee), irrespective of the number of committees on which such director serves as Chair or as a member (collectively the “Committee Membership Retainers”). Committee Membership Retainers shall be payable quarterly in arrears, subject to such director’s continued service to the Company as a member of a committee on the last day of the preceding quarter. Such amounts shall be prorated in the case of service for less than the entire quarter.
Equity Award
Initial Award for New Directors
On the date a new Non-Employee Director becomes a member of the Board, each such Non-Employee Director shall automatically receive an option (an “Initial Option”) to purchase 60,000 shares of the common stock of the Company (each, a “Share”). The per share exercise price for the Initial Option shall be equal to the fair market value for a Share on the date of grant. The Initial Option shall vest and becomes exercisable in three equal annual installments, with one-third of the Shares subject to the Initial Option vesting on each of the first three anniversaries of the date of grant, subject to such director’s continued board service through each applicable vesting date. An employee director who ceases to be an employee, but who remains a director, will not receive the Initial Equity Awards. For the avoidance of doubt, no Initial Options will be granted to existing members of the Board in connection with the closing of the initial public offering of the Company.
Annual Award for Continuing Board Members
At each Company’s annual meeting of stockholders, all Non-Employee Directors shall automatically receive an option (an “Annual Option”) to purchase 20,000 Shares. The per share exercise price for the Annual Option shall be equal to the fair market value for a Share on the date of grant. The Annual Option shall vest and becomes exercisable on the earlier of (x) the one year anniversary of the date of grant of the Annual Option and (y) the date of the Company’s next annual meeting of stockholders following the date of grant, subject to such director’s continued board service through such vesting date.
Provisions Applicable to All Equity Awards
Each Initial Option and Annual Option shall be subject to the terms and conditions of the Company’s 2015 Omnibus Equity Incentive Plan (the “2015 Equity Plan”) and the terms of the Stock Option Agreement entered into by the Company and such director in connection with such award. For purposes of this Director Compensation Policy, “fair market value” shall have the meaning as set forth in the 2015 Equity Plan. Furthermore, all vesting for any such equity
2
awards to Non-Employee Directors shall terminate, and all such equity awards shall be fully vested, upon a “Change in Control” as defined in the 2015 Equity Plan.
Expense Reimbursement
The Company shall reimburse each director, consistent with the Company’s travel and expense reimbursement policies and practices, for all reasonable out-of-pocket expenses incurred by any director of the Company directly in connection with travel to and from any meetings of the Board or committees thereof. The Company shall make expense reimbursements to all directors within a reasonable amount of time following submission by the director of reasonable written substantiation for the expenses.
3
